Anita Katharina Wagner

11PUBLICATIONS
38CO-AUTHORS
PharmacogenomicsMolecular targetsCancer diagnosisNanotoxicology, health and safetyPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 28, 2026
Completion and outcomes of postmarketing requirements and commitments issued by the US Food and Drug Administration for new drugs, 2016-24: cross sectional evaluation of postmarketing studies.

|Jul 22, 2026
Oral Targeted Anticancer Medications: Use and Spending by Evidence and Magnitude of Clinical Benefit, 2016-2021.

|Dec 23, 2025
Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration's accelerated approval pathway: retrospective observational study and economic evaluation.

Huseyin Naci, Mahnum Shahzad, Peter Murphy

|Aug 28, 2023
Changing Tides? Anticancer Biologic and Biosimilar Use in Medicare Part B, 2019-2021.

Alison R McClean, Anita K Wagner, Christine Y Lu

|Mar 29, 2023
Communication of anticancer drug benefits and related uncertainties to patients and clinicians: document analysis of regulated information on prescription drugs in Europe.

Courtney Davis, Anita K Wagner, Maximilian Salcher-Konrad

|Jul 15, 2022
New-Onset Cancer Cases in FDA's Sentinel System: A Large Distributed System of US Electronic Healthcare Data.

Nicole R Haug, Anita K Wagner, Katherine A McGlynn

Pageof 2

Frequent Collaborators

3 joint publications

Alessandra Ferrario

3 joint publications

J Frank Wharam

3 joint publications

Dennis Ross-Degnan

3 joint publications

Huseyin Naci